Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wilson, Wyndham H, Prof, O'Connor, Owen A, Prof, Czuczman, Myron S, Prof, LaCasce, Ann S, MD, Gerecitano, John F, MD, Leonard, John P, Prof, Tulpule, Anil, MD, Dunleavy, Kieron, MD, Xiong, Hao, PhD, Chiu, Yi-Lin, PhD, Cui, Yue, PhD, Busman, Todd, MS, Elmore, Steven W, PhD, Rosenberg, Saul H, PhD, Krivoshik, Andrew P, MD, Enschede, Sari H, MD, Humerickhouse, Rod A, MD
Published in The lancet oncology (01.12.2010)
Published in The lancet oncology (01.12.2010)
Get full text
Journal Article
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zhou, Zheng, Sehn, Laurie H., Rademaker, Alfred W., Gordon, Leo I., LaCasce, Ann S., Crosby-Thompson, Allison, Vanderplas, Ann, Zelenetz, Andrew D., Abel, Gregory A., Rodriguez, Maria A., Nademanee, Auayporn, Kaminski, Mark S., Czuczman, Myron S., Millenson, Michael, Niland, Joyce, Gascoyne, Randy D., Connors, Joseph M., Friedberg, Jonathan W., Winter, Jane N.
Published in Blood (06.02.2014)
Published in Blood (06.02.2014)
Get full text
Journal Article
Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype
Hernandez‐Ilizaliturri, Francisco J., Deeb, George, Zinzani, Pier L., Pileri, Stefano A., Malik, Farhana, Macon, William R., Goy, Andre, Witzig, Thomas E., Czuczman, Myron S.
Published in Cancer (15.11.2011)
Published in Cancer (15.11.2011)
Get full text
Journal Article
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Dunleavy, Kieron, Pittaluga, Stefania, Czuczman, Myron S., Dave, Sandeep S., Wright, George, Grant, Nicole, Shovlin, Margaret, Jaffe, Elaine S., Janik, John E., Staudt, Louis M., Wilson, Wyndham H.
Published in Blood (11.06.2009)
Published in Blood (11.06.2009)
Get full text
Journal Article
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Palanca-Wessels, Maria Corinna A, Dr, Czuczman, Myron, Prof, Salles, Gilles, Prof, Assouline, Sarit, MD, Sehn, Laurie H, MD, Flinn, Ian, MD, Patel, Manish R, MD, Sangha, Randeep, MD, Hagenbeek, Anton, MD, Advani, Ranjana, MD, Tilly, Herve, Prof, Casasnovas, Olivier, MD, Press, Oliver W, Prof, Yalamanchili, Sreeni, PharmD, Kahn, Robert, MD, Dere, Randall C, BSc, Lu, Dan, PhD, Jones, Surai, MS, Jones, Cheryl, ScD, Chu, Yu-Waye, MD, Morschhauser, Franck, Prof
Published in The lancet oncology (01.06.2015)
Published in The lancet oncology (01.06.2015)
Get full text
Journal Article
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Advani, Anjali, Coiffier, Bertrand, Czuczman, Myron S, Dreyling, Martin, Foran, James, Gine, Eva, Gisselbrecht, Christian, Ketterer, Nicolas, Nasta, Sunita, Rohatiner, Ama, Schmidt-Wolf, Ingo G H, Schuler, Martin, Sierra, Jorge, Smith, Mitchell R, Verhoef, Gregor, Winter, Jane N, Boni, Joseph, Vandendries, Erik, Shapiro, Mark, Fayad, Luis
Published in Journal of clinical oncology (20.04.2010)
Published in Journal of clinical oncology (20.04.2010)
Get full text
Journal Article
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Czuczman, Myron S, Trněný, Marek, Davies, Andrew, Rule, Simon, Linton, Kim M, Wagner-Johnston, Nina, Gascoyne, Randy D, Slack, Graham W, Brousset, Pierre, Eberhard, David A, Hernandez-Ilizaliturri, Francisco J, Salles, Gilles, Witzig, Thomas E, Zinzani, Pier Luigi, Wright, George W, Staudt, Louis M, Yang, Yandan, Williams, P Mickey, Lih, Chih-Jian, Russo, Jacqueline, Thakurta, Anjan, Hagner, Patrick, Fustier, Pierre, Song, Dale, Lewis, Ian D
Published in Clinical cancer research (01.08.2017)
Published in Clinical cancer research (01.08.2017)
Get full text
Journal Article
In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma
Hutchings, Martin, Kostakoglu, Lale, Zaucha, Jan Maciej, Malkowski, Bogdan, Biggi, Alberto, Danielewicz, Iwona, Loft, Annika, Specht, Lena, Lamonica, Dominick, Czuczman, Myron S, Nanni, Christina, Zinzani, Pier Luigi, Diehl, Louis, Stern, Richard, Coleman, Morton
Published in Journal of clinical oncology (01.09.2014)
Published in Journal of clinical oncology (01.09.2014)
Get full text
Journal Article
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre‐B‐ALL
Awasthi, Aradhana, Ayello, Janet, Van de Ven, Carmella, Elmacken, Mona, Sabulski, Anthony, Barth, Matthew J., Czuczman, Myron S., Islam, Humayun, Klein, Christian, Cairo, Mitchell S.
Published in British journal of haematology (01.12.2015)
Published in British journal of haematology (01.12.2015)
Get full text
Journal Article
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents
Xue, Kai, Gu, Juan J., Zhang, Qunling, Mavis, Cory, Hernandez-Ilizaliturri, Francisco J., Czuczman, Myron S., Guo, Ye
Published in Journal of cancer research and clinical oncology (01.02.2016)
Published in Journal of cancer research and clinical oncology (01.02.2016)
Get full text
Journal Article
Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
Chu, Yaya, Hochberg, Jessica, Yahr, Ashlin, Ayello, Janet, van de Ven, Carmella, Barth, Matthew, Czuczman, Myron, Cairo, Mitchell S
Published in Cancer immunology research (01.04.2015)
Published in Cancer immunology research (01.04.2015)
Get more information
Journal Article
Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma: Results From a Multicenter Study
KAHL, Brad S, BARTLETT, Nancy L, CHESON, Bruce D, LEONARD, John P, LING CHEN, GANJOO, Kristen, WILLIAMS, Michael E, CZUCZMAN, Myron S, SUE ROBINSON, K, JOYCE, Robin, VAN DER JAGT, Richard H
Published in Cancer (2010)
Published in Cancer (2010)
Get full text
Journal Article
Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
CZUCZMAN, Myron S, OLEJNICZAK, Scott, GOWDA, Aruna, KOTOWSKI, Adam, BINDER, Arvinder, KAUR, Harman, KNIGHT, Joy, STAROSTIK, Petr, DEANS, Julie, HERNANDEZ-LLIZALITURRI, Francisco J
Published in Clinical cancer research (01.03.2008)
Published in Clinical cancer research (01.03.2008)
Get full text
Journal Article
Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development
Gu, Juan J, Singh, Anil, Xue, Kai, Mavis, Cory, Barth, Matthew, Yanamadala, Vivek, Lenz, Peter, Grau, Michael, Lenz, Georg, Czuczman, Myron S, Hernandez-Ilizaliturri, Francisco J
Published in Oncotarget (09.01.2018)
Published in Oncotarget (09.01.2018)
Get full text
Journal Article
Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study
CHANAN-KHAN, Asher, MILLER, Kena C, SPANER, David, MOHR, Alice, BYRNE, Catriona, HERNANDEZ-ILIZALITURRI, Francisco, CHRYSTAL, Cynthia, STAROSTIK, Petr, CZUCZMAN, Myron S, MUSIAL, Laurie, LAWRENCE, David, PADMANABHAN, Swaminathan, TAKESHITA, Kenichi, PORTER, Carl W, GOODRICH, David W, BERNSTEIN, Zale P, WALLACE, Paul
Published in Journal of clinical oncology (01.12.2006)
Published in Journal of clinical oncology (01.12.2006)
Get full text
Journal Article
Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo
Reddy, Nishitha, Hernandez‐Ilizaliturri, Francisco J., Deeb, George, Roth, Mark, Vaughn, Mary, Knight, Joy, Wallace, Paul, Czuczman, Myron S.
Published in British journal of haematology (01.01.2008)
Published in British journal of haematology (01.01.2008)
Get full text
Journal Article
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016
Press, Oliver W, Unger, Joseph M, Rimsza, Lisa M, Friedberg, Jonathan W, LeBlanc, Michael, Czuczman, Myron S, Kaminski, Mark, Braziel, Rita M, Spier, Catherine, Gopal, Ajay K, Maloney, David G, Cheson, Bruce D, Dakhil, Shaker R, Miller, Thomas P, Fisher, Richard I
Published in Journal of clinical oncology (20.01.2013)
Published in Journal of clinical oncology (20.01.2013)
Get full text
Journal Article
Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up
CZUCZMAN, Myron S, WEAVER, Robin, ALKUZWENY, Baha, BERLFEIN, Judy, GRILLO-LOPEZ, Antonio J
Published in Journal of clinical oncology (01.12.2004)
Published in Journal of clinical oncology (01.12.2004)
Get full text
Journal Article